Progesterone receptor antagonists and selective progesterone receptor modulators: proven and potential clinical applications

Irving M. Spitz
In: Expert Review of Obstetrics & Gynecology · 2007 · vol. 2(2) , pp. 227–242 · doi:10.1586/17474108.2.2.227 · W2118791538
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Progesterone receptor antagonists and modulators have proven uses in pregnancy termination and show potential for treating gynecological conditions, though some long-term users exhibit endometrial thickening that may not be true hyperplasia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Progesterone receptor antagonists (PAs) and selective progesterone receptor modulators (SPRMs) are members of the progesterone receptor ligand family. The PA mifepristone is usually used as a single dose for short-term indications, such as pregnancy termination, cervical dilation, fetal death and emergency contraception. In view of their antiproliferative effect on the endometrium and their ability to produce amenorrhea, both PAs and SPRMs may be used long term in the treatment of uterine myoma and endometriosis. They may also have applications in dysfunctional uterine bleeding, breast and ovarian carcinoma, contraception and, possibly, in postmenopausal women as a form of estrogen-free replacement therapy. Despite the endometrial antiproliferative effect, during long-term administration of these drugs some women have developed endometrial thickening on ultrasound. This may be interpreted as endometrial hyperplasia, although experienced pathologists have doubted whether this is true hyperplasia.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK